Opdivo (nivolumab)

pCPA File Number: 22337

Negotiation Status:

Concluded with an LOI

Indication(s):

Resectable Non-small cell lung cancer (tumours ≥4cm or node positive), neoadjuvant treatment of adult patients, when used in combination with platinum-doublet chemotherapy

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0303-000

pCPA Engagement Letter Issued:

2023-05-10

Negotiation Process Concluded:

2023-05-25